Amedisys Reports Fourth Quarter and Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys (AMED) Misses Q4 EPS by 2c, Offers Guidance
February 27, 2018 5:03 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.56, $0.02 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $404.2 million versus the consensus estimate of $394.62 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $2.97-$3.08, may not compare to the consensus... More
